Fuller & Thaler Asset Management Inc. trimmed its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,300 shares of the company’s stock after selling 1,400 shares during the quarter. Fuller & Thaler Asset Management Inc.’s holdings in IDEXX Laboratories were worth $4,089,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of IDEXX Laboratories by 4.0% during the second quarter. Vanguard Group Inc. now owns 9,264,579 shares of the company’s stock worth $1,495,488,000 after acquiring an additional 354,024 shares during the last quarter. BlackRock Inc. grew its stake in IDEXX Laboratories by 10.5% during the second quarter. BlackRock Inc. now owns 7,100,374 shares of the company’s stock worth $1,146,142,000 after purchasing an additional 673,347 shares during the period. Koch Industries Inc. grew its stake in IDEXX Laboratories by 44,533.1% during the second quarter. Koch Industries Inc. now owns 1,399,248 shares of the company’s stock worth $1,391,000 after purchasing an additional 1,396,113 shares during the period. Renaissance Technologies LLC grew its stake in IDEXX Laboratories by 38.6% during the second quarter. Renaissance Technologies LLC now owns 1,351,900 shares of the company’s stock worth $218,224,000 after purchasing an additional 376,300 shares during the period. Finally, Arrowstreet Capital Limited Partnership grew its stake in IDEXX Laboratories by 42.8% during the second quarter. Arrowstreet Capital Limited Partnership now owns 1,310,660 shares of the company’s stock worth $211,567,000 after purchasing an additional 392,790 shares during the period. Institutional investors own 88.41% of the company’s stock.
In other IDEXX Laboratories news, CEO Jonathan W. Ayers sold 18,000 shares of the firm’s stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $153.75, for a total value of $2,767,500.00. Following the completion of the sale, the chief executive officer now owns 1,064,573 shares of the company’s stock, valued at $163,678,098.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman Jonathan W. Ayers sold 13,000 shares of the firm’s stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $150.79, for a total value of $1,960,270.00. Following the completion of the sale, the chairman now directly owns 1,044,034 shares of the company’s stock, valued at approximately $157,429,886.86. The disclosure for this sale can be found here. Insiders sold 121,000 shares of company stock valued at $18,334,330 in the last three months. Insiders own 2.77% of the company’s stock.
IDXX has been the subject of several recent analyst reports. Zacks Investment Research raised IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 target price for the company in a research note on Tuesday, October 24th. Stifel Nicolaus reaffirmed a “buy” rating and set a $185.00 target price on shares of IDEXX Laboratories in a research note on Tuesday, October 24th. BidaskClub cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Canaccord Genuity reaffirmed a “buy” rating and set a $180.00 target price on shares of IDEXX Laboratories in a research note on Friday, October 6th. Finally, CL King raised IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 target price for the company in a research note on Friday, July 28th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. IDEXX Laboratories currently has a consensus rating of “Hold” and an average price target of $173.67.
Shares of IDEXX Laboratories, Inc. (NASDAQ IDXX) opened at $154.06 on Friday. The company has a quick ratio of 0.77, a current ratio of 0.95 and a debt-to-equity ratio of -12.48. IDEXX Laboratories, Inc. has a one year low of $113.47 and a one year high of $173.01. The company has a market capitalization of $13,436.91, a P/E ratio of 51.87, a price-to-earnings-growth ratio of 2.33 and a beta of 0.46.
IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, October 31st. The company reported $0.79 EPS for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.05. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. The firm had revenue of $492.00 million during the quarter, compared to analysts’ expectations of $492.94 million. During the same quarter last year, the firm posted $0.62 earnings per share. The company’s revenue for the quarter was up 9.7% compared to the same quarter last year. equities research analysts expect that IDEXX Laboratories, Inc. will post 3.24 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece of content was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://ledgergazette.com/2017/11/24/fuller-thaler-asset-management-inc-has-4-09-million-stake-in-idexx-laboratories-inc-idxx.html.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.